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Abstract
Thiamine (Vitamin B1) is an essential vitamin that must be obtained from the diet for proper neurological function. At higher
doses, thiamine and benfotiamine (S-benzoylthiamine O-monophosphate, BT)–a phosphorylated derivative of thiamine–
have antinociceptive effects in animals and humans, although how these compounds inhibit pain is unknown. Here, we
found that Prostatic acid phosphatase (PAP, ACPP) can dephosphorylate BT in vitro, in dorsal root ganglia (DRG) neurons
and in primary-afferent axon terminals in the dorsal spinal cord. The dephosphorylated product S-benzoylthiamine (S-BT)
then decomposes to O-benzoylthiamine (O-BT) and to thiamine in a pH-dependent manner, independent of additional
enzymes. This unique reaction mechanism reveals that BT only requires a phosphatase for conversion to thiamine. However,
we found that the antinociceptive effects of BT, thiamine monophosphate (TMP) and thiamine–a compound that is not
phosphorylated–were entirely dependent on PAP at the spinal level. Moreover, pharmacokinetic studies with wild-type and
Pap2/2 mice revealed that PAP is not required for the conversion of BT to thiamine in vivo. Taken together, our study
highlights an obligatory role for PAP in the antinociceptive effects of thiamine and phosphorylated thiamine analogs, and
suggests a novel phosphatase-independent function for PAP.
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Introduction
In mammals, thiamine is an essential dietary supplement and is
important for neurotransmission and neurological function
[1,2,3,4,5]. Thiamine is absorbed in the intestine and transported
from the extracellular space by thiamine transport receptors
(THTR1 and THTR2, also called SLC19A2 and SLC19A3,
respectively) [6,7,8]. Thiamine exists as the free molecule as well as
in the form of several phosphate esters: thiamine monophosphate
(TMP), thiamine diphosphate (TDP, also called thiamine pyro-
phosphate), and thiamine triphosphate (TTP) [9]. Inside cells,
TDP is an important coenzyme in several biochemical processes,
including carbohydrate and amino acid metabolism [10,11,12].
Additionally, several naturally occurring thiaminylated adenine
nucleotides are found in bacteria and mammalian tissues
[13,14,15]. Prokaryotes and eukaryotes thus contain a diverse
repertoire of thiamine analogs.
In humans, thiamine deficiency causes Beriberi, a disease with
neurological symptoms that include pain, neuropathy and memory
loss. Thiamine deficiency is also associated with Wernicke-
Korsakoff syndrome, Alzheimer’s disease, and diabetes
[16,17,18,19]. Thiamine deficiency can be treated by administer-
ing thiamine or compounds of the allithiamine class, the most
commonly studied of which is BT [20,21,22,23].
When administered at higher doses, thiamine and BT have
antinociceptive effects in animal models of inflammatory pain and
neuropathic pain [24,25,26,27,28,29] and analgesic effects in
humans, including patients with diabetic neuropathic pain
[30,31,32]. Thiamine and BT are inexpensive and readily
available over-the-counter, yet these compounds are not routinely
used to treat chronic pain. In vitro, thiamine reduces nerve injury-
induced hyperexcitability and modulates tetrodotoxin-resistant
sodium currents in cultured small-to-medium diameter, presum-
ably nociceptive, DRG neurons [25]. Currently, it is unknown
what genes are required for the in vivo antinociceptive effects of
thiamine and BT.
Recently, we found that the transmembrane isoform of PAP is
expressed in small-to-medium diameter DRG neurons and
dephosphorylates TMP extracellularly in these neurons and their
spinal axon terminals [33,34]. In light of these observations, we
hypothesized that PAP might be required to dephosphorylate BT
and mediate the antinociceptive effects of BT in vivo. Here, we
tested this hypothesis using biochemical, genetic and pharmaco-
kinetic approaches. Unexpectedly, we found that the antinocicep-
tive effects of BT and thiamine–a compound that does not contain
a phosphate group–were entirely dependent on PAP. Our findings
suggest a novel, phosphatase independent, function for PAP in
controlling the in vivo antinociceptive activity of thiamine and
phosphorylated thiamine analogs.
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Materials and Methods
Ethics Statement
All procedures and behavioral experiments involving vertebrate
animals were approved by the Institutional Animal Care and Use
Committee at the University of North Carolina at Chapel Hill.
In vitro LC-MS Assay
Fresh BT (S-benzoylthiamine O-monophosphate, Sigma-Al-
drich) was prepared in water prior to each experiment (100 mg/
mL stock). Contrary to what has been reported [22], BT is soluble
in water [35]. The phosphate group can be deprotonated to
facilitate dissolution in water. We heated BT in a tightly-capped
tube at 55uC and added 15 mL of 1 N NaOH every 10 min
followed by vortexing until the solid was completely in solution.
BT is susceptible to base hydrolysis if NaOH is added too quickly.
BT hydrolysis can be further minimized by adding NaOH only
after the solid is fully sedimented. The final pH was approximately
8.0. Prior to each experiment, we analyzed our stock BT solution
by LC-MS to confirm that no hydrolysis products were present.
The reaction of BT with hPAP was monitored in vitro using LC-
MS. Samples containing BT (15 mg/mL, 1100 mL total volume)
were diluted in one of three different buffers: 100 mM sodium
acetate, pH 5.3; 100 mM HEPES, pH 7.0; or 100 mM Tris,
pH 8.5. Samples were incubated at 37uC and the reaction was
initiated with the addition of hPAP (3.25 U diluted in 0.9% saline,
Sigma-Aldrich). Aliquots (200 mL) were removed to a fresh
microcentrifuge tube at 0, 5, 15, 30, 45 and 60 min. Reactions
were terminated by adding methanol (480 mL) and chloroform
(160 mL) to precipitate the protein, followed by addition of water
(640 mL) and vortex mixing. After centrifugation (2,152 x g for
5 min at room temperature), the aqueous methanol-water phase
was transferred to a separate microcentrifuge tube for analysis.
LC-MS analysis was performed at room temperature on an
Agilent ZORBAX Eclipse Plus C18 Rapid Resolution HT column
(4.6 x 50 mm, 1.8 mm). Mobile phase A was water and mobile
phase B was methanol, which were both supplemented with 0.1%
acetic acid. Samples were run with the following gradient (1 mL/
min flow rate, 7 min total run time): 10%–100% B in 5 min, hold
at 100% B for 2 min, and return to starting conditions in a 1 min
post-run. Sample injection volume was 5 mL. Peak area was
quantified using the Agilent ChemStation software. Only peaks
associated with the predicted mass for a given BT metabolite were
quantified.
Animals
All experiments were performed as previously described with
male mice during the light phase, raised under a 12:12 light:dark
cycle [33]. C57BL/6 mice (2–4 months in age) were purchased
from Jackson Laboratories, and Pap2/2 and A1R
2/2 mice were
backcrossed to C57BL/6J mice for 12 generations. A1R
2/2,
Pap2/2 double knockout mice were generated by breeding
backcrossed A1R
2/2 and Pap2/2 mice.
Figure 1. BT is dephosphorylated by PAP and then non-catalytically converted to thiamine. (A,B) LC-MS analysis of BT (3 mg/mL) and
reaction products pre- and post-addition of hPAP (0.65 U) at acidic, neutral and alkaline pH values. Reactions were performed in vitro at 37uC for the
indicated times. Only peaks with the expected mass values were integrated and analyzed. (B) Analyte peak areas for BT, intermediates (S-BT, O-BT)
and thiamine. Reactions were performed in triplicate and the data are plotted as means 6 s.e.m. (C) Reaction pathway. BT is stable at all pH values in
the absence of PAP. Upon dephosphorylation, the intermediates (S-BT, O-BT) decompose to thiamine in a pH-dependent manner. These latter
reactions proceed in vitro in the absence of enzymes (Fig. 2,3).
doi:10.1371/journal.pone.0048562.g001
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Drugs and Injections
Intrathecal injections (5 mL) were performed using acute lumbar
puncture without anesthesia [36]. BT (from stock, made as
described above), thiamine monophosphate hydrochloride (TMP),
thiamine hydrochloride, thiamine pyrophosphate (TDP) and
thiochrome were purchased from Sigma-Aldrich and diluted in
0.9% saline. Prior to injection, the purity of the final BT solution
was monitored by LC-MS as described above. A metal gavage
needle fitted to a syringe was used to deliver vehicle/BT p.o.
Behavior
All mice were acclimated to the experimenter, the room and the
experimental apparatus for 3–5 days prior to behavioral testing.
Thermal sensitivity was monitored using the Hargreaves method,
where the radiant heat source was calibrated to elicit a paw
withdrawal reflex of approximately 10 s in naı¨ve mice (cutoff time
of 20 s). Complete Freund’s adjuvant (20 mL, MP Biomedicals)
was injected under the glabrous skin to inflame one hindpaw.
Spared nerve injury (SNI) was used to model neuropathic pain
[33,37].
Tissue Collection
Vehicle (0.9% saline) or BT (10–300 mg/kg) was administered
to adult male wild-type and Pap2/2 mice (2–4 months in age) by
oral gavage (100 mL/mouse). One hour post-treatment, mice were
given a lethal dosage of pentobarbital (50 mg/kg, i.p.). The chest
cavity was opened and blood was withdrawn by direct cardiac
puncture from the right atrium using a sterile 1 mL syringe with a
23 gauge, L inch needle (BD Biosciences). The needle was
removed, and the blood was immediately added to a tube
containing 250 I.U. heparin sodium salt (Sigma-Aldrich). The
liver, kidneys, brain, DRG and spinal cord were removed and
flash frozen on dry ice. All samples were stored at 280uC prior to
homogenization.
Thiochrome Detection by HPLC
Samples were prepared in pre-tared screw-cap centrifuge tubes
with 6 zirconium oxide beads (1.4 mm, Bertin Technologies) and
3–5 volumes 10% trichloroacetic acid depending on tissue weight.
In addition, a single 2.8 mm zirconium oxide bead was added to
the kidney samples to aid in homogenization. Tissues were
homogenized in the Precellys 24 (Bertin Technologies) at 4uC
(5,000 x g, 25 s, 3 cycles). Samples were incubated on ice for
15 min. and the protein and insoluble fraction was harvested by
centrifugation (13,000 x g for 6 min). The aqueous phase was
extracted with 2 x 2 mL water-saturated methyl t-butyl ether
(MTBE) in glass test tubes. Thiamine metabolites were oxidized to
thiochrome derivatives with the addition of potassium ferric
cyanide (0.6 mM in 15% NaOH). Sample preparation and all
chromatographic steps were performed as previously described
[38].
Histology
Enzyme histochemistry was performed as described previously
[33]. Briefly, tissue sections were washed twice with 40 mM
Trizma-Maleate (TM) buffer, pH 7.0, and once with TM buffer
containing 8% (w/v) sucrose. The tissue was then incubated for
2 hr and 37uC in TM buffer with 8% sucrose (w/v), 6 mM BT,
and 2.4 mM lead nitrate (made fresh prior to use). Samples were
washed with 2% acetic acid for 1 min, and three times with TM
Figure 2. S-BT is non-enzymatically converted to O-BT and thiamine in vitro. (A) HPLC analysis of chromatographically purified S-BT (1 mg/
mL) in methanol and (B) in aqueous solutions buffered at acidic, neutral and alkaline pH values (t = 0 and 30 min, respectively at 37uC). (C) Analyte
peak areas for S-BT metabolites generated in vitro. Data are plotted as the total peak area observed at each time point.
doi:10.1371/journal.pone.0048562.g002
PAP Required for Thiamine and BT Antinociception
PLOS ONE | www.plosone.org 3 October 2012 | Volume 7 | Issue 10 | e48562
buffer. Samples were treated with 1% sodium sulfide for 10 sec
and washed several times with phosphate-buffered saline (PBS),
pH 7.4.
Results
BT is a PAP Substrate and Decomposes to Thiamine
Upon Dephosphorylation
To determine if PAP could dephosphorylate BT in vitro, we
incubated purified human (h)PAP protein (the secretory isoform)
with BT then monitored reaction products over time by liquid
chromatography mass spectrometry (LC-MS). We found that
hPAP dephosphorylated BT to S-BT at an acidic pH and neutral
pH but S-BT was not detected at an alkaline pH (Fig. 1A,B). Peaks
for O-BT and thiamine appeared at all pH values, with O-BT
production favored at pH 7.0, and thiamine production favored at
pH 8.5. The structures of all compounds are shown in Fig. 1C.
It was previously assumed that S-BT was converted to thiamine
via a thioesterase-dependent mechanism [39]. However, no
thioesterases were present in our in vitro reactions, suggesting
thiamine was produced via an alternative reaction mechanism. To
determine if thiamine could be generated in a non-enzymatic
fashion from S-BT and O-BT, we purified the S-BT and O-BT
reaction intermediates by high-performance liquid chromatogra-
phy (HPLC; Fig. 2A and 3A, respectively), then monitored the
stability of these compounds in the absence of enzymes.
Intriguingly, we found that S-BT underwent an intramolecular
rearrangement to O-BT at pH 5.3 and pH 7.0, then partially
decomposed to thiamine at pH 8.5 (Fig. 2B-C). Likewise, purified
O-BT was stable at pH 5.3 and pH 7.0 then decomposed to
thiamine at pH 8.5 (Fig. 1C, 3B-C). Taken together, our data
reveals that BT is stable in vitro in the absence of enzymes.
However, once BT is dephosphorylated at physiological pH, S-
BT, O-BT and thiamine are produced (Fig. 1C). BT thus only
requires a phosphatase for conversion to thiamine.
PAP Dephosphorylates BT in Nociceptive Circuits
We previously found that TMP is a PAP-specific substrate in
nociceptive neurons [33]. To determine if PAP could also
dephosphorylate BT in small-to-medium diameter, presumably
nociceptive neurons, we performed BT enzyme histochemistry
with sections of DRG and spinal cord from wild-type and Pap2/2
mice. We found that small-to-medium diameter neurons and their
axon terminals in lamina II of the spinal cord were intensely
stained at pH 7.0 in wild-type mice (Fig. 4A,C,E) but were not
intensely stained in Pap2/2 mice (Fig. 4B,D,F). Thus PAP can
dephosphorylate BT extracellularly in DRG neurons and in dorsal
spinal cord.
The Antinociceptive Effects of BT, TMP and Thiamine are
PAP-dependent
Since PAP can dephosphorylate BT in vitro and in nociceptive
neurons, we next hypothesized that PAP might be required for the
antinociceptive effects of BT but not thiamine. To test this
hypothesis, we intrathecally (i.t.) injected wild-type and Pap2/2
mice with these compounds, then monitored noxious thermal
sensitivity in the hindpaw. Consistent with previous studies
Figure 3. O-BT is non-enzymatically converted to thiamine in vitro. (A) HPLC analysis of chromatographically purified O-BT (1 mg/mL) in
methanol and (B) in aqueous solutions buffered at acidic, neutral and alkaline pH values (t = 0 and 30 min, respectively at 37uC). (C) Analyte peak
areas for O-BT and thiamine generated in vitro. Data are plotted as the total peak area observed at each time point.
doi:10.1371/journal.pone.0048562.g003
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[24,25,29], we found that thiamine (50 nmol, Fig. 5A) and BT
(100 nmol, Fig. 5B) increased paw withdrawal latency for 5 hr,
highlighting a thermal antinociceptive effect for these compounds.
The antinociceptive effect of BT was dose-dependent in wild-type
mice (EC50 = 11.4 nmol, Fig. 5C). Strikingly, the antinociceptive
activity of each compound was completely absent in the Pap2/2
mice (Fig. 5A-C). The lack of activity following BT administration
was predicted; however, the lack of activity following thiamine
administration–a compound that is not phosphorylated–was
unexpected. These data unexpectedly revealed that PAP was
required for the biological activity of BT and thiamine, suggesting
a phosphatase-independent function for PAP in vivo.
Since thiamine exists in a variety of forms in vivo, we postulated
that PAP might instead elicit antinociceptive effects by generating
an alternate thiamine metabolite. If this were the case, we could
bypass a requirement for PAP by injecting this putative metabolite,
and show it has PAP-independent antinociceptive effects. Thus, to
test this hypothesis, we studied the antinociceptive properties of
several commercially-available thiamine derivatives: two phos-
phorylated metabolites (TMP and TDP) and the oxidation
product of thiamine (thiochrome) (Figure 6). Following i.t.
administration, we found that neither TDP (25 nmol) nor
thiochrome (25 nmol) had antinociceptive effects in wild-type or
Pap2/2 mice (Fig. 6A and C, respectively). In contrast, the PAP-
specific substrate, TMP (100 nmol), was active in wild-type mice
but not Pap2/2 mice (Fig. 6B). Since none of these metabolites
acted independent of PAP, none of these compounds are likely to
be an active, PAP-independent, metabolite in vivo.
Figure 4. PAP dephosphorylates BT in small-to-medium diameter DRG neurons and afferent axon terminals in the spinal cord. (A–F)
Sections from wild-type and Pap2/2 mouse (A,B) DRG and (C–F) spinal cord stained using enzyme histochemistry (6 mM BT at pH 7.0). Scale bar,
50 mm in (B,D), 500 mm in (F).
doi:10.1371/journal.pone.0048562.g004
PAP Required for Thiamine and BT Antinociception
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Pharmacokinetic Profile of Oral BT in Wild-type and
Pap2/2 Mice
Given that BT had no antinociceptive effects in Pap2/2 mice,
we next sought to determine if Pap2/2 mice were unable to absorb
or metabolize BT when administered orally. To address this, we
administered a range of BT doses (0–300 mg/kg, p.o.) to wild-type
and Pap2/2 mice, sacrificed the mice 1 hr later, and then collected
six different tissues for analysis (Fig. 7). Several metabolites of BT
(thiamine, TMP, TDP) can be monitored in tissue homogenates by
HPLC after conversion to fluorescent thiochrome derivatives
[9,22,38]. In wild-type and Pap2/2 mice, we found that thiamine
concentration increased in a dose-dependent manner in each
tissue studied, with the largest increases in concentration observed
in peripheral tissues (blood, liver, kidney, and DRG) (Fig. 7A,B).
This included a small but significant dose-dependent increase of
thiamine concentration in the brain (2.3 fold increase at 300 mg/
kg BT dose), consistent with previous studies [18]. We also
observed a dose-dependent increase in TMP in the blood and
peripheral tissues of wild-type and Pap2/2 mice (Fig. 7C,D). TDP
levels were dose-dependently elevated only in the blood of both
strains (Fig. 7E,F). Importantly, there were no significant
differences in thiamine, TMP or TDP concentration between
wild-type and Pap2/2 mice at any dose or in any tissue. Wild-type
and Pap2/2 mice are thus equally capable of absorbing and
metabolizing BT to thiamine, TMP and TDP. This data suggest
that other phosphatases, such as alkaline phosphatases [22,39],
metabolize BT to thiamine in vivo.
Antinociceptive Effects of BT Require PAP at the Spinal
Level
Though we were unable to resolve precisely why PAP was
required for the antinociceptive effects of BT in vivo, we next
sought to determine if BT had PAP-dependent antinociceptive
effects when delivered systemically via a therapeutically relevant
route, namely orally (via oral gavage; p.o.). It has been
demonstrated previously that BT is more readily absorbed from
the intestine than thiamine [22,23,39]. Following oral delivery, we
found that BT (p.o.) had thermal antinociceptive effects in wild-
Figure 5. The thermal antinociceptive effects of thiamine and BT, when delivered spinally, are entirely dependent on PAP. (A,B)
Wild-type and Pap2/2 male mice were tested for noxious thermal sensitivity (hindpaw, radiant heating) before (baseline, BL) and following i.t.
injection of (A) 50 nmol thiamine (n = 30 mice/group) or (B) 100 nmol BT (n = 20 mice/group). Paired t tests were used to compare responses at each
time point to BL responses. *P,0.05, **P,0.005, ***P,0.0005. (C) BT (i.t.) dose-response. Thermal sensitivity monitored for 5 hr after injecting BT i.t.
(0.01–100 nmol). Plotted as area under the curve. n = 10 mice per group. Data were fit by non-linear regression to a sigmoidal dose response
equation, and the EC50 value was calculated in GraphPad Prism. Data plotted as means 6 s.e.m.
doi:10.1371/journal.pone.0048562.g005
Figure 6. TMP, but not other thiamine metabolites, inhibits noxious thermal sensitivity in a PAP-dependent manner. (A–C) Wild-type
and Pap2/2 male mice were tested for noxious thermal sensitivity (hindpaw, radiant heating) before (baseline, BL) and following i.t. injection of (A)
25 nmol TDP (n = 10 wild-type mice, n = 9 Pap2/2 mice), (B) 100 nmol TMP (n = 17 wild-type mice, n = 18 Pap2/2 mice) and (C) 25 nmol thiochrome
(n = 10 wild-type mice, n = 9 Pap2/2 mice). (A–C) T tests were used to compare responses at each time point to baseline (BL). *P,0.05, **P,0.005,
***P,0.0005. Data are plotted as means 6 s.e.m.
doi:10.1371/journal.pone.0048562.g006
PAP Required for Thiamine and BT Antinociception
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type mice but not Pap2/2 mice at all doses tested (Fig. 8A,B, with
EC50 = 69.1 mg/kg in wild-type mice). These data and our data
above collectively reveal that PAP is required for the antinocicep-
tive effects of BT when delivered spinally or systemically.
BT also has thermal antihyperalgesic effects in models of
chronic pain [28]. To determine if these thermal antihyperalgesic
effects were PAP-dependent, we administered BT (p.o.) to wild-
type and Pap2/2 mice after inflaming one hindpaw with Complete
Figure 7. Pharmacokinetic profiles of thiamine, TMP and TDP do not differ between wild-type and Pap2/2 mice following oral
administration of BT. (A–F) BT (0–300 mg/kg, p.o.) was administered to wild-type and Pap2/2 mice (n = 5/dose). The indicated tissues were
harvested 1 h post oral gavage then were homogenized in 10% trichloroacetic acid. Fluorescent thiochrome derivatives were monitored by reversed
phase HPLC to detect (A–B) thiamine, (C–D) TMP, and (E–F) TDP. Peak area values were converted to units of concentration for each thiamine
derivative and normalized by the weight of tissue in each replicate. There were no significant differences between wild-type and Pap2/2 mice. Data
are plotted as means 6 s.e.m.
doi:10.1371/journal.pone.0048562.g007
PAP Required for Thiamine and BT Antinociception
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Freund’s adjuvant (CFA; a model of inflammatory pain; Fig. 9A).
We also evaluated BT in the spared nerve injury (SNI) model of
neuropathic pain (Fig. 9B). In both chronic pain models, BT
(300 mg/kg, p.o.) inhibited thermal hypersensitivity in the
inflamed/injured paw of wild-type mice but had no effect in
Pap2/2 mice, thus revealing a requirement for PAP in the thermal
antihyperalgesic effects of systemic BT.
BT reportedly has mechanical antiallodynic effects in models of
neuropathic pain [28]. Although, others found that the BT
metabolite thiamine does not have antiallodynic effects [25,29].
Consistent with these latter studies, we found that BT (300 mg/kg,
p.o.) did not have mechanical antiallodynic effects in wild-type or
Pap2/2 mice following CFA-induced inflammation or SNI surgery
(data not shown, using an electronic von Frey apparatus to
monitor mechanical allodynia).
PAP is expressed in nociceptive neurons in DRG as well as
other tissues of the body [33,40]. To determine if the antinoci-
ceptive effects of systemic BT were dependent on PAP at the spinal
level, we next performed a biochemical rescue experiment with
Pap2/2 mice. This experiment was based on our observation that
hPAP had A1R-dependent antinociceptive effects that lasted 3
days when injected i.t. [33]. We reasoned that we could inject
hPAP (250 mU, i.t.) into Pap2/2 mice and restore PAP activity at
the spinal level in an otherwise Pap-deficient background. As part
of this experiment, we generated Pap2/2, A1R
2/2 double
knockout mice, to prevent the A1R-dependent antinociceptive
effects of hPAP [33] from obscuring the antinociceptive effects of
BT.
We then monitored noxious thermal sensitivity in Pap2/2,
A1R
2/2 mice before and after injecting vehicle or hPAP (i.t.)
(Fig. 10). In parallel, A1R
2/2 mice were injected with hPAP (i.t.) as
a control. One day later, we administered BT (300 mg/kg, p.o.)
systemically to all the mice. Remarkably, systemic BT inhibited
thermal nociception in Pap2/2, A1R
2/2 mice that received hPAP
(i.t.) but had no effect in Pap2/2, A1R
2/2 mice that received
vehicle (i.t.) (Fig. 10). We then administered BT (p.o.) to these
same hPAP injected mice one week later, a time when spinal hPAP
is no longer active [33]. This second BT (p.o.) dose was no longer
Figure 8. The thermal antinociceptive effect of BT, when delivered orally, is entirely dependent on PAP. (A) Wild-type (n = 21) and
Pap2/2 (n = 15) male mice were tested for noxious thermal sensitivity (hindpaw, radiant heating) before (BL) and following oral administration of BT
(300 mg/kg, p.o.). Paired t tests were used to compare responses at each time point to BL responses. *P,0.05, ***P,0.0005. (B) BT (p.o.) dose-
response. Thermal sensitivity monitored for 5 hr after administering BT orally (0.1–300 mg/kg). Plotted as area under the curve. n = 10 male mice per
group. The data were fit by non-linear regression to a sigmoidal dose response equation, and the EC50 value was calculated in GraphPad Prism. Data
are plotted as means 6 s.e.m.
doi:10.1371/journal.pone.0048562.g008
Figure 9. BT has thermal antihyperalgesic effects in chronic inflammatory and neuropathic pain models that are entirely PAP-
dependent. (A) Inflammatory pain model. CFA was injected into the hindpaw of wild-type (n = 20) and Pap2/2 (n = 9) male mice, then BT (300 mg/
kg, p.o.) was administered 1 day later. Thermal sensitivity monitored at the indicated times in the inflamed hindpaw. (B) Neuropathic pain model. The
sural and common peroneal branches of the sciatic nerve were ligated and then transected in wild-type (n = 28) and Pap2/2 (n = 20) male mice. BT
(300 mg/kg, p.o.) was administered 2 days later. Thermal sensitivity monitored at the indicated times in the nerve-injured hindpaw. T tests were used
to compare responses between wild-type and Pap2/2 mice. *P,0.05, **P,0.005, ***P,0.0005. Data are plotted as means 6 s.e.m.
doi:10.1371/journal.pone.0048562.g009
PAP Required for Thiamine and BT Antinociception
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effective in Pap2/2, A1R
2/2 mice (Fig. 8, black squares) but
remained effective in the A1R
2/2 controls (Fig. 10, red line).
Taken together, this biochemical rescue experiment reveals that
the antinociceptive effects of systemic BT administration were
entirely due to PAP activity at the spinal level. Additionally, since
BT was active in A1R
2/2 mice, this experiment indicates that BT
and its metabolites do not inhibit nociception via A1R.
Discussion
At low doses, thiamine acts as a vitamin and is essential for
cellular and neurological functions. At higher doses, thiamine and
BT have antinociceptive effects in animal models of inflammatory
pain and neuropathic pain [24,25,26,28,29]. Thiamine and BT
also have analgesic effects in humans, including patients with
diabetic neuropathic pain [30,31,32], though the analgesic effects
in these human studies are admittedly modest. More clinical
studies are certainly needed to assess safety and efficacy of BT
[23,41]. In addition, little is known about how thiamine and BT
inhibit nociception at a mechanistic level. This lack of clinical and
preclinical knowledge likely limits the use of these inexpensive and
readily-available (over the counter) compounds to treat some
forms of chronic pain.
Previously, we found that PAP could dephosphorylate extracel-
lular TMP in DRG and the spinal cord of mice [33], raising the
possibility that PAP might dephosphorylate the related analog BT
to thiamine, and hence mediate the antinociceptive properties of
BT. We directly tested this possibility by assessing the extent to
which PAP dephosphorylates BT in vitro and vivo and by studying
the importance of PAP in BT-mediated antinociception.
We found that BT is a substrate for PAP in vitro and that BT
histochemical staining was eliminated in Pap2/2 mouse tissue. The
latter experiments provide genetic support that PAP dephosphor-
ylates BT in nociceptive neurons and afferent terminals in the
spinal dorsal horn. The necessity of PAP was further demonstrated
in vivo, as the antinociceptive effects of BT were eliminated in
Pap2/2 mice but could be rescued following spinal administration
of PAP protein.
These data initially suggested that PAP might be required to
convert BT to thiamine in vivo. Since thiamine does not contain a
phosphate group, we predicted thiamine would have antinocicep-
tive effects independent of PAP. However, to our surprise, we
found that the antinociceptive effects of thiamine were also
dependent on PAP, suggesting that PAP might have other, non-
phosphatase-related functions in vivo.
For example, PAP might transphosphorylate thiamine to TMP
or TDP. Previous studies have shown that alkaline phosphatases
and acid phosphatases, including PAP, can transphosphorylate
substrates in the presence of phosphate donor compounds
[42,43,44,45]. In principle, this transphosphorylation activity
could be bypassed in vivo by injecting TMP or TDP directly into
Pap2/2 mice. However, we found that TDP (i.t.) had no
antinociceptive effects in wild-type or Pap2/2 mice (Fig. 6A),
and TMP (i.t.) was active only in wild-type mice (Fig. 6B). Since
neither TDP nor TMP had PAP-independent antinociceptive
effects, we conclude that these metabolites are not downstream of
PAP and do not serve as the active compounds. Instead, the
antinociceptive effects of TMP also require PAP, placing TMP
upstream of PAP in this biochemical pathway.
Alternatively, we considered the possibility that PAP might
directly or indirectly oxidize thiamine. Thiamine is oxidized to
thiochrome in vivo [46], and thiochrome can positively modulate a
class of muscarinic acetylcholine receptors that inhibit nociception
[47,48,49]. Following direct spinal administration, we found that
thiochrome had no antinociceptive properties in wild-type or
Pap2/2 mice (Fig. 6C), making it unlikely that the antinociceptive
effects of BT, TMP or thiamine occur via metabolism and
oxidation to thiochrome.
Lastly, if PAP functioned in vivo as a phosphatase for BT or
TMP, we would predict a buildup of one or more phosphorylated
metabolites (i.e., TMP) coupled with a subsequent decrease in
another metabolite (i.e., thiamine) in the Pap2/2 mice. However,
the pharmacokinetic profiles revealed no difference in thiamine,
TMP or TDP levels between the two strains. Since all of these BT
metabolites were present at normal levels in Pap2/2 mice, our data
suggests that other enzymes, such as alkaline phosphatases [39],
facilitate absorption and metabolism of BT.
Further studies will be needed to determine precisely why PAP
is required for the antinociceptive effects of BT, TMP and
thiamine. Our data support a number of possibilities, including
that a) PAP might transform thiamine into an active compound via
a novel catalytic activity, b) PAP could serve as a thiamine/
thiamine analog receptor or be an essential subunit of such a
receptor, or c) PAP could facilitate binding of thiamine or
thiamine analogs to a receptor. Indeed, the antinociceptive effects
of thiamine and BT are maximal within the first hour post-
delivery, suggesting that all of these compounds act via a receptor-
dependent mechanism. BT can also inhibit biochemical pathways
implicated in hyperglycemic damage [27,31,50], although inhibi-
Figure 10. Rescue experiment reveals that PAP is exclusively required at the spinal level to mediate the antinociceptive effects of
systemic BT. hPAP (P; 250 mU) was injected i.t. into A1R
2/2,Pap2/2 (n = 10) and A1R
2/2 (n = 10) male mice. Vehicle (V; 0.9% saline) was injected into
a separate group of A1R
2/2, Pap2/2 (n = 10) male mice. BT (300 mg/kg, p.o.) was administered 24 h later. One week later, BT (300 mg/kg, p.o.) was
again administered to the mice that were previously injected with hPAP. Noxious thermal sensitivity in the hindpaw was measured at the indicated
times. Paired t tests were used to compare responses at each time point to the response before administration of BT. *P,0.05, **P,0.005,
***P,0.0005. Data are plotted as means 6 s.e.m.
doi:10.1371/journal.pone.0048562.g010
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tion of these pathways was detected after 6 hr, well after the rapid-
onset antinociceptive effects of BT.
In summary, our study reveals an essential and unexpected role
for PAP in mediating the antinociceptive effects of BT, TMP and
thiamine. This function is distinct from the ectonucleotidase
activity of PAP [33]. Our study also suggests a novel in vivo
function for PAP that is unrelated to its phosphatase activity. Our
mechanistic findings will encourage further research into BT and
analogs and suggest a broader role for PAP in regulating thiamine-
dependent processes throughout the body [40].
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